JP2003514808A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003514808A5 JP2003514808A5 JP2001538892A JP2001538892A JP2003514808A5 JP 2003514808 A5 JP2003514808 A5 JP 2003514808A5 JP 2001538892 A JP2001538892 A JP 2001538892A JP 2001538892 A JP2001538892 A JP 2001538892A JP 2003514808 A5 JP2003514808 A5 JP 2003514808A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- branched
- partially
- twenty
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 99
- -1 prinyl Chemical group 0.000 description 98
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 32
- 125000003545 alkoxy group Chemical group 0.000 description 26
- 229910052717 sulfur Inorganic materials 0.000 description 23
- 125000004076 pyridyl group Chemical group 0.000 description 21
- 125000001624 naphthyl group Chemical group 0.000 description 17
- 229910052760 oxygen Inorganic materials 0.000 description 17
- 150000001875 compounds Chemical class 0.000 description 15
- 125000000623 heterocyclic group Chemical group 0.000 description 15
- 229910052736 halogen Inorganic materials 0.000 description 14
- 150000002367 halogens Chemical class 0.000 description 14
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 12
- 125000002883 imidazolyl group Chemical group 0.000 description 12
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 12
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 11
- 125000005843 halogen group Chemical group 0.000 description 11
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 11
- 125000000714 pyrimidinyl group Chemical group 0.000 description 11
- 125000004093 cyano group Chemical group *C#N 0.000 description 10
- 125000001072 heteroaryl group Chemical group 0.000 description 10
- 125000004043 oxo group Chemical group O=* 0.000 description 10
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 10
- 125000000168 pyrrolyl group Chemical group 0.000 description 10
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000001257 hydrogen Substances 0.000 description 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 9
- 125000003373 pyrazinyl group Chemical group 0.000 description 9
- 125000003282 alkyl amino group Chemical group 0.000 description 8
- 125000003226 pyrazolyl group Chemical group 0.000 description 8
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 125000003342 alkenyl group Chemical group 0.000 description 6
- 125000000304 alkynyl group Chemical group 0.000 description 6
- 125000002541 furyl group Chemical group 0.000 description 6
- 150000002431 hydrogen Chemical class 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 125000002098 pyridazinyl group Chemical group 0.000 description 6
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 6
- 125000001544 thienyl group Chemical group 0.000 description 6
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 5
- 125000003118 aryl group Chemical group 0.000 description 5
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 description 5
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 5
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 5
- 125000001041 indolyl group Chemical group 0.000 description 5
- 125000001786 isothiazolyl group Chemical group 0.000 description 5
- 125000000842 isoxazolyl group Chemical group 0.000 description 5
- 125000003386 piperidinyl group Chemical group 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 4
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 4
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 125000004193 piperazinyl group Chemical group 0.000 description 4
- 125000005494 pyridonyl group Chemical group 0.000 description 4
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 4
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 4
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
- 125000003831 tetrazolyl group Chemical group 0.000 description 4
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 description 3
- ZGXFVYOWURGVSM-UHFFFAOYSA-N 4-[4-(2-morpholin-4-yl-2-thiomorpholin-4-ylthiomorpholin-4-yl)sulfinyl-2-thiomorpholin-4-ylthiomorpholin-2-yl]morpholine Chemical compound C1CSC(N2CCSCC2)(N2CCOCC2)CN1S(=O)N(C1)CCSC1(N1CCSCC1)N1CCOCC1 ZGXFVYOWURGVSM-UHFFFAOYSA-N 0.000 description 3
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 3
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 3
- 125000002933 cyclohexyloxy group Chemical class C1(CCCCC1)O* 0.000 description 3
- 125000005436 dihydrobenzothiophenyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 125000005241 heteroarylamino group Chemical group 0.000 description 3
- 125000005553 heteroaryloxy group Chemical group 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 150000002825 nitriles Chemical class 0.000 description 3
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- NNLBRYQGMOYARS-UHFFFAOYSA-N thiane 1-oxide Chemical compound O=S1CCCCC1 NNLBRYQGMOYARS-UHFFFAOYSA-N 0.000 description 3
- ZQKVJTVUSZBVQO-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylphenyl)-3-(4-pyridin-3-yloxynaphthalen-1-yl)urea Chemical compound CC1=CC=C(C(C)(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OC1=CC=CN=C1 ZQKVJTVUSZBVQO-UHFFFAOYSA-N 0.000 description 2
- WQCKNOHLEAQFAP-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylphenyl)-3-(4-pyridin-4-yloxynaphthalen-1-yl)urea Chemical compound CC1=CC=C(C(C)(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OC1=CC=NC=C1 WQCKNOHLEAQFAP-UHFFFAOYSA-N 0.000 description 2
- ZFKFZYAWPJMVGZ-UHFFFAOYSA-N 1-(5-tert-butyl-2-methylphenyl)-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea Chemical compound CC1=CC=C(C(C)(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OCCN1CCOCC1 ZFKFZYAWPJMVGZ-UHFFFAOYSA-N 0.000 description 2
- XXHQUBQLTYBRTG-UHFFFAOYSA-N 1-(5-tert-butyl-2-morpholin-4-ylphenyl)-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea Chemical compound C=1C=C(OCCN2CCOCC2)C2=CC=CC=C2C=1NC(=O)NC1=CC(C(C)(C)C)=CC=C1N1CCOCC1 XXHQUBQLTYBRTG-UHFFFAOYSA-N 0.000 description 2
- QYCGBAJADAGLLK-UHFFFAOYSA-N 1-(cyclohepten-1-yl)cycloheptene Chemical group C1CCCCC=C1C1=CCCCCC1 QYCGBAJADAGLLK-UHFFFAOYSA-N 0.000 description 2
- VSIYJQNFMOOGCU-UHFFFAOYSA-N 1-(cyclohexen-1-yl)cyclohexene Chemical group C1CCCC(C=2CCCCC=2)=C1 VSIYJQNFMOOGCU-UHFFFAOYSA-N 0.000 description 2
- XVLWJROIONAKQB-UHFFFAOYSA-N 1-[3-bromo-5-tert-butyl-2-(2-morpholin-4-ylethylamino)phenyl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea Chemical compound C=1C=C(OCCN2CCOCC2)C2=CC=CC=C2C=1NC(=O)NC1=CC(C(C)(C)C)=CC(Br)=C1NCCN1CCOCC1 XVLWJROIONAKQB-UHFFFAOYSA-N 0.000 description 2
- MGKPCLNUSDGXGT-UHFFFAOYSA-N 1-benzofuran-3-one Chemical compound C1=CC=C2C(=O)COC2=C1 MGKPCLNUSDGXGT-UHFFFAOYSA-N 0.000 description 2
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 description 2
- QRCGFTXRXYMJOS-UHFFFAOYSA-N 4h-1,4-benzoxazin-3-one Chemical compound C1=CC=C2NC(=O)COC2=C1 QRCGFTXRXYMJOS-UHFFFAOYSA-N 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- YPWFISCTZQNZAU-UHFFFAOYSA-N Thiane Chemical compound C1CCSCC1 YPWFISCTZQNZAU-UHFFFAOYSA-N 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 150000004982 aromatic amines Chemical class 0.000 description 2
- 125000003435 aroyl group Chemical group 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 2
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 2
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 2
- 125000001664 diethylamino group Chemical group [H]C([H])([H])C([H])([H])N(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000005046 dihydronaphthyl group Chemical group 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 2
- 125000004853 tetrahydropyridinyl group Chemical group N1(CCCC=C1)* 0.000 description 2
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 2
- BUGOPWGPQGYYGR-UHFFFAOYSA-N thiane 1,1-dioxide Chemical compound O=S1(=O)CCCCC1 BUGOPWGPQGYYGR-UHFFFAOYSA-N 0.000 description 2
- 125000001425 triazolyl group Chemical group 0.000 description 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 description 1
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 description 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 description 1
- DKROPLKBDHUKRT-UHFFFAOYSA-N 1-[4-(2-aminopyridin-4-yl)oxynaphthalen-1-yl]-3-(5-tert-butyl-2-methylphenyl)urea Chemical compound CC1=CC=C(C(C)(C)C)C=C1NC(=O)NC(C1=CC=CC=C11)=CC=C1OC1=CC=NC(N)=C1 DKROPLKBDHUKRT-UHFFFAOYSA-N 0.000 description 1
- NZUUXQSBKZPFKK-UHFFFAOYSA-N 4-piperazin-1-ylmorpholine Chemical compound C1CNCCN1N1CCOCC1 NZUUXQSBKZPFKK-UHFFFAOYSA-N 0.000 description 1
- KQTGCJMBUBYSLL-UHFFFAOYSA-N 4-piperidin-1-ylmorpholine Chemical compound C1CCCCN1N1CCOCC1 KQTGCJMBUBYSLL-UHFFFAOYSA-N 0.000 description 1
- SSXTZEGNWOYWNY-UHFFFAOYSA-N 6,7,8,9-tetrahydro-5h-cyclohepta[b]pyrazine Chemical compound C1CCCCC2=NC=CN=C21 SSXTZEGNWOYWNY-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- JPZCTPYNLCZLQB-UHFFFAOYSA-N CC(=O)NC1=C(C(=CC(=C1)C(C)(C)C)NC(=O)NC2C(=CC3=CC=NC=C3)C=CC4=CC=CC=C24)OC Chemical compound CC(=O)NC1=C(C(=CC(=C1)C(C)(C)C)NC(=O)NC2C(=CC3=CC=NC=C3)C=CC4=CC=CC=C24)OC JPZCTPYNLCZLQB-UHFFFAOYSA-N 0.000 description 1
- DQXOHEONGSWKRM-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C(=C1)NC(=O)N(C)C)OC)NC(=O)NC2C(=CC3=CC=NC=C3)C=CC4=CC=CC=C24 Chemical compound CC(C)(C)C1=CC(=C(C(=C1)NC(=O)N(C)C)OC)NC(=O)NC2C(=CC3=CC=NC=C3)C=CC4=CC=CC=C24 DQXOHEONGSWKRM-UHFFFAOYSA-N 0.000 description 1
- VGXRGIMBBBUPCJ-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C(=C1)NC(=O)N2CCOCC2)OC)NC(=O)NC3C(=CC4=CC=NC=C4)C=CC5=CC=CC=C35 Chemical compound CC(C)(C)C1=CC(=C(C(=C1)NC(=O)N2CCOCC2)OC)NC(=O)NC3C(=CC4=CC=NC=C4)C=CC5=CC=CC=C35 VGXRGIMBBBUPCJ-UHFFFAOYSA-N 0.000 description 1
- RVYCZCKPTXJYGZ-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C(=C1)OC)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)N)C4=CC=CC=C24 Chemical compound CC(C)(C)C1=CC(=C(C(=C1)OC)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)N)C4=CC=CC=C24 RVYCZCKPTXJYGZ-UHFFFAOYSA-N 0.000 description 1
- HJGYWSBTOJFHEK-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C(=C1)OC)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)NC)C4=CC=CC=C24 Chemical compound CC(C)(C)C1=CC(=C(C(=C1)OC)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)NC)C4=CC=CC=C24 HJGYWSBTOJFHEK-UHFFFAOYSA-N 0.000 description 1
- IOUUKLOBUSZXNL-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C(=C1)OC)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)OC)C4=CC=CC=C24 Chemical compound CC(C)(C)C1=CC(=C(C(=C1)OC)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)OC)C4=CC=CC=C24 IOUUKLOBUSZXNL-UHFFFAOYSA-N 0.000 description 1
- HMOJKZVAYIDXRR-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C=C1)OC)NC(=O)NC2=CCC(=CC3=CC(=C)NC=C3)C4=CC=CC=C24 Chemical compound CC(C)(C)C1=CC(=C(C=C1)OC)NC(=O)NC2=CCC(=CC3=CC(=C)NC=C3)C4=CC=CC=C24 HMOJKZVAYIDXRR-UHFFFAOYSA-N 0.000 description 1
- HNNCJPPPIVJDRG-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(C=C1)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)OC)C4=CC=CC=C24 Chemical compound CC(C)(C)C1=CC(=C(C=C1)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)OC)C4=CC=CC=C24 HNNCJPPPIVJDRG-UHFFFAOYSA-N 0.000 description 1
- KZBTYTJSQCUCCE-UHFFFAOYSA-N CC(C)(C)C1=CC(=C(N=C1)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)N)C4=CC=CC=C24 Chemical compound CC(C)(C)C1=CC(=C(N=C1)OC)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)N)C4=CC=CC=C24 KZBTYTJSQCUCCE-UHFFFAOYSA-N 0.000 description 1
- RRCDKJIRBWEMIT-UHFFFAOYSA-N CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C=C3CC=C(C4=CC=CC=C34)NC(=O)NC5=C(C(=CC(=C5)C(C)(C)C)OC)OC Chemical compound CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C=C3CC=C(C4=CC=CC=C34)NC(=O)NC5=C(C(=CC(=C5)C(C)(C)C)OC)OC RRCDKJIRBWEMIT-UHFFFAOYSA-N 0.000 description 1
- UWVJQHGDCLERCS-UHFFFAOYSA-N CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C=C3CC=C(C4=CC=CC=C34)NC(=O)NC5=C(N=CC(=C5)C(C)(C)C)OC Chemical compound CC(C1=CC=CC=C1)NC2=NC=CC(=C2)C=C3CC=C(C4=CC=CC=C34)NC(=O)NC5=C(N=CC(=C5)C(C)(C)C)OC UWVJQHGDCLERCS-UHFFFAOYSA-N 0.000 description 1
- KJIXACNTXVJWGL-UHFFFAOYSA-N CC1=C(C=C(C=C1)C(C)(C)C)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)N)C4=CC=CC=C24 Chemical compound CC1=C(C=C(C=C1)C(C)(C)C)NC(=O)NC2=CCC(=CC3=CC(=NC=C3)N)C4=CC=CC=C24 KJIXACNTXVJWGL-UHFFFAOYSA-N 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- KMTRUDSVKNLOMY-UHFFFAOYSA-N Ethylene carbonate Chemical compound O=C1OCCO1 KMTRUDSVKNLOMY-UHFFFAOYSA-N 0.000 description 1
- 206010051920 Glomerulonephropathy Diseases 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical class O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 125000003113 cycloheptyloxy group Chemical class C1(CCCCCC1)O* 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- XOVJAYNMQDTIJD-UHFFFAOYSA-N cyclopentobarbital Chemical compound C1CC=CC1C1(CC=C)C(=O)NC(=O)NC1=O XOVJAYNMQDTIJD-UHFFFAOYSA-N 0.000 description 1
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 125000004652 decahydroisoquinolinyl group Chemical group C1(NCCC2CCCCC12)* 0.000 description 1
- 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 125000004582 dihydrobenzothienyl group Chemical group S1C(CC2=C1C=CC=C2)* 0.000 description 1
- 125000005043 dihydropyranyl group Chemical group O1C(CCC=C1)* 0.000 description 1
- 125000005044 dihydroquinolinyl group Chemical group N1(CC=CC2=CC=CC=C12)* 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000005883 dithianyl group Chemical group 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 208000024908 graft versus host disease Diseases 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000004926 indolenyl group Chemical group 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 208000037931 necrotizing enteritis Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 125000005968 oxazolinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000005545 phthalimidyl group Chemical group 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
- RAOIDOHSFRTOEL-UHFFFAOYSA-N tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 1
- ISXOBTBCNRIIQO-UHFFFAOYSA-N tetrahydrothiophene 1-oxide Chemical compound O=S1CCCC1 ISXOBTBCNRIIQO-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000002769 thiazolinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000005503 thioxanyl group Chemical group 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- YFHICDDUDORKJB-UHFFFAOYSA-N trimethylene carbonate Chemical compound O=C1OCCCO1 YFHICDDUDORKJB-UHFFFAOYSA-N 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16590399P | 1999-11-16 | 1999-11-16 | |
| US60/165,903 | 1999-11-16 | ||
| PCT/US2000/031582 WO2001036403A1 (en) | 1999-11-16 | 2000-11-16 | Urea derivatives as anti-inflammatory agents |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003514808A JP2003514808A (ja) | 2003-04-22 |
| JP2003514808A5 true JP2003514808A5 (https=) | 2008-01-10 |
| JP4955171B2 JP4955171B2 (ja) | 2012-06-20 |
Family
ID=22600951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001538892A Expired - Lifetime JP4955171B2 (ja) | 1999-11-16 | 2000-11-16 | 抗炎症剤としての尿素誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US6492393B1 (https=) |
| EP (1) | EP1232150B1 (https=) |
| JP (1) | JP4955171B2 (https=) |
| AT (1) | ATE375334T1 (https=) |
| AU (1) | AU1617901A (https=) |
| CA (1) | CA2389360C (https=) |
| DE (1) | DE60036726T2 (https=) |
| ES (1) | ES2292488T3 (https=) |
| MX (2) | MXPA02004594A (https=) |
| WO (1) | WO2001036403A1 (https=) |
Families Citing this family (98)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2160899A (en) * | 1997-12-11 | 1999-06-28 | Janssen Pharmaceutica N.V. | Retinoic acid mimetic anilides |
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US20020065296A1 (en) * | 1999-01-13 | 2002-05-30 | Bayer Corporation | Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors |
| WO2000042012A1 (en) * | 1999-01-13 | 2000-07-20 | Bayer Corporation | φ-CARBOXYARYL SUBSTITUTED DIPHENYL UREAS AS RAF KINASE INHIBITORS |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE538794T1 (de) | 1999-01-13 | 2012-01-15 | Bayer Healthcare Llc | Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer |
| US6806274B1 (en) * | 1999-07-07 | 2004-10-19 | Astrazeneca Uk Limited | Quinazoline derivatives |
| US6645990B2 (en) | 2000-08-15 | 2003-11-11 | Amgen Inc. | Thiazolyl urea compounds and methods of uses |
| DE60137273D1 (de) * | 2000-10-20 | 2009-02-12 | Eisai R&D Man Co Ltd | Verfahren zur Herstellung von 4-Phenoxy chinolin Derivaten |
| US6962926B2 (en) | 2001-01-31 | 2005-11-08 | Telik, Inc. | Antagonist of MCP-1 function, and compositions and methods of use thereof |
| US6670364B2 (en) | 2001-01-31 | 2003-12-30 | Telik, Inc. | Antagonists of MCP-1 function and methods of use thereof |
| US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| WO2002092576A1 (en) * | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
| EP1395561A1 (en) | 2001-05-25 | 2004-03-10 | Boehringer Ingelheim Pharmaceuticals Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
| AU2002310156A1 (en) | 2001-06-05 | 2002-12-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-disubstituted benzo-fused cycloalkyl urea compounds |
| JP2004536845A (ja) | 2001-07-11 | 2004-12-09 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン媒介疾患の治療方法 |
| EP1438048A1 (en) | 2001-10-18 | 2004-07-21 | Boehringer Ingelheim Pharmaceuticals Inc. | 1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors |
| MXPA04007830A (es) | 2002-02-11 | 2005-07-01 | Bayer Pharmaceuticals Corp | Arilureas como inhibidores de cinasa. |
| MXPA04007832A (es) | 2002-02-11 | 2005-09-08 | Bayer Pharmaceuticals Corp | Aril-ureas con actividad inhibitoria de angiogenesis. |
| WO2003068229A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| US20040023961A1 (en) * | 2002-02-11 | 2004-02-05 | Bayer Corporation | Aryl ureas with raf kinase and angiogenisis inhibiting activity |
| ATE386030T1 (de) | 2002-02-25 | 2008-03-15 | Boehringer Ingelheim Pharma | 1,4-disubstituierte benzokondensierte cycloalkyl- harnstoffverbindungen zur behandlung von zytokinvermittelten erkrankungen |
| DE60310730T2 (de) | 2002-07-09 | 2007-05-16 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische zusammensetzungen aus anticholinergica und p38 kinase hemmern zur behandlung von erkrankungen der atemwege |
| CA2494824A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes |
| AU2003277285B2 (en) * | 2002-10-04 | 2007-12-13 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
| DE602004030222D1 (de) * | 2003-02-28 | 2011-01-05 | Bayer Healthcare Llc | 2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| EP1608639A2 (en) | 2003-02-28 | 2005-12-28 | Bayer Pharmaceuticals Corporation | Novel bicyclic urea derivatives useful in the treatment of cancer and other disorders |
| US7078419B2 (en) * | 2003-03-10 | 2006-07-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Cytokine inhibitors |
| WO2004113274A2 (en) | 2003-05-20 | 2004-12-29 | Bayer Pharmaceuticals Corporation | Diaryl ureas with kinase inhibiting activity |
| EA010485B1 (ru) | 2003-07-23 | 2008-10-30 | Байер Фамэсьютиклс Копэрейшн | Производное n,n'-дифенилмочевины, фармацевтическая композиция (варианты) и способ лечения и предупреждения заболеваний и состояний с его использованием (варианты) |
| US7749999B2 (en) | 2003-09-11 | 2010-07-06 | Itherx Pharmaceuticals, Inc. | Alpha-ketoamides and derivatives thereof |
| US7683172B2 (en) | 2003-11-11 | 2010-03-23 | Eisai R&D Management Co., Ltd. | Urea derivative and process for preparing the same |
| US20070161677A1 (en) * | 2004-01-30 | 2007-07-12 | Merck Patent Gmbh | Bisarylurea derivatives |
| CN101010315A (zh) * | 2004-04-30 | 2007-08-01 | 拜耳制药公司 | 用于治疗癌症的取代的吡唑基脲衍生物 |
| JP5080970B2 (ja) | 2004-06-17 | 2012-11-21 | サイトキネティクス・インコーポレーテッド | 心疾患を治療するための置換尿素誘導体 |
| AU2011253934C1 (en) * | 2004-06-17 | 2013-08-22 | Cytokinetics, Inc. | Substituted urea derivatives for treating cardiac diseases |
| US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
| AU2005283422C1 (en) | 2004-09-17 | 2017-02-02 | Eisai R & D Management Co., Ltd. | Medicinal composition |
| CA2584185C (en) * | 2004-10-13 | 2014-07-15 | Frank Stieber | Heterocyclic substituted bisarylurea derivates as kinase inhibitors |
| KR20120137420A (ko) * | 2004-11-24 | 2012-12-20 | 아보트 러보러터리즈 | 바닐로이드 수용체 아형 1(ｖｒ1) 수용체를 억제하는 크로마닐우레아 화합물 및 이의 용도 |
| EP1824843A2 (en) | 2004-12-07 | 2007-08-29 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| JP2008523071A (ja) * | 2004-12-07 | 2008-07-03 | ルーカス ファーマシューティカルズ， インコーポレイテッド | Ｍａｐキナーゼの尿素インヒビター |
| PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
| WO2007015578A1 (ja) | 2005-08-02 | 2007-02-08 | Eisai R & D Management Co., Ltd. | 血管新生阻害物質の効果を検定する方法 |
| GB2431927B (en) | 2005-11-04 | 2010-03-17 | Amira Pharmaceuticals Inc | 5-Lipoxygenase-activating protein (FLAP) inhibitors |
| US8399666B2 (en) | 2005-11-04 | 2013-03-19 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| US7977359B2 (en) | 2005-11-04 | 2011-07-12 | Amira Pharmaceuticals, Inc. | 5-lipdxygenase-activating protein (FLAP) inhibitors |
| TW200808321A (en) | 2005-12-15 | 2008-02-16 | Cytokinetics Inc | Certain chemical entities, compositions and methods |
| CA2635888A1 (en) * | 2006-01-04 | 2007-07-19 | Locus Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| RU2448708C3 (ru) | 2006-05-18 | 2017-09-28 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Противоопухолевое средство против рака щитовидной железы |
| CN101511793B (zh) | 2006-08-28 | 2011-08-03 | 卫材R&D管理有限公司 | 针对未分化型胃癌的抗肿瘤剂 |
| CN101600694A (zh) | 2007-01-29 | 2009-12-09 | 卫材R&D管理有限公司 | 未分化型胃癌治疗用组合物 |
| EP1992344A1 (en) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation |
| KR101513326B1 (ko) | 2007-11-09 | 2015-04-17 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 혈관 신생 저해 물질과 항종양성 백금 착물의 병용 |
| JP5791500B2 (ja) | 2008-05-23 | 2015-10-07 | パンミラ ファーマシューティカルズ，エルエルシー． | ５−リポキシゲナーゼ活性化タンパク質阻害剤 |
| US8546431B2 (en) | 2008-10-01 | 2013-10-01 | Panmira Pharmaceuticals, Llc | 5-lipoxygenase-activating protein (FLAP) inhibitors |
| DK2468281T3 (en) | 2009-08-19 | 2016-03-21 | Eisai R&D Man Co Ltd | Quinolinderivatholdig pharmaceutical composition |
| US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
| AU2011223790A1 (en) * | 2010-03-01 | 2012-08-30 | Myrexis, Inc. | Compounds and therapeutic uses thereof |
| GB201009731D0 (en) * | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
| WO2011162343A1 (ja) | 2010-06-25 | 2011-12-29 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | キナーゼ阻害作用を有する化合物の併用による抗腫瘍剤 |
| CN103402519B (zh) | 2011-04-18 | 2015-11-25 | 卫材R&D管理有限公司 | 肿瘤治疗剂 |
| JP6038128B2 (ja) | 2011-06-03 | 2016-12-07 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| CN103917536B (zh) | 2011-10-03 | 2016-07-06 | 瑞斯比维特有限公司 | 1-吡唑基-3-(4-((2-(苯氨基)嘧啶-4-基)氧基)萘-1-基)脲用作p38 MAP激酶抑制剂 |
| CA2867175A1 (en) * | 2012-03-28 | 2013-10-03 | Neuropore Therapies, Inc. | Phenyl-urea and phenyl-carbamate derivatives as inhibitors of protein aggregation |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| US20150225373A1 (en) | 2012-08-29 | 2015-08-13 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| US20150210722A1 (en) | 2012-08-29 | 2015-07-30 | Respivert Limited | Kinase inhibitors |
| EP2890701B1 (en) | 2012-08-29 | 2017-03-29 | Respivert Limited | Kinase inhibitors |
| WO2014076484A1 (en) | 2012-11-16 | 2014-05-22 | Respivert Limited | Kinase inhibitors |
| AU2013364953A1 (en) | 2012-12-21 | 2015-04-30 | Eisai R&D Management Co., Ltd. | Amorphous form of quinoline derivative, and method for producing same |
| EP2970190A1 (en) | 2013-03-14 | 2016-01-20 | Respivert Limited | Kinase inhibitors |
| US9771353B2 (en) | 2013-04-02 | 2017-09-26 | Topivert Pharma Limited | Kinase inhibitors based upon N-alkyl pyrazoles |
| KR102283876B1 (ko) | 2013-04-02 | 2021-07-29 | 옥슬러 액퀴지션즈 리미티드 | 키나제 저해제로서 유용한 우레아 유도체 |
| EP2997377B1 (en) | 2013-05-14 | 2018-07-18 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds |
| EP3083604A1 (en) * | 2013-12-20 | 2016-10-26 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| ES2677595T3 (es) | 2014-02-14 | 2018-08-03 | Respivert Limited | Compuestos heterocíclicos aromáticos como compuestos antiinflamatorios |
| PT3524595T (pt) | 2014-08-28 | 2022-09-19 | Eisai R&D Man Co Ltd | Derivado de quinolina altamente puro e método para produção do mesmo |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| AU2016224583B2 (en) | 2015-02-25 | 2021-06-03 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
| KR102662228B1 (ko) | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| EP3287441B1 (en) | 2015-04-20 | 2021-06-09 | Takeda Pharmaceutical Company Limited | Acylated 4-aminopiperidines as inhibitors of serine palmitoyltransferase |
| BR112017027227B1 (pt) | 2015-06-16 | 2023-12-12 | Eisai R&D Management Co., Ltd | Agente anti-câncer |
| JP6553726B2 (ja) | 2015-08-20 | 2019-07-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療剤 |
| CA3015978A1 (en) | 2016-04-06 | 2017-10-12 | Topivert Pharma Limited | Kinase inhibitors |
| WO2018074461A1 (ja) | 2016-10-18 | 2018-04-26 | 武田薬品工業株式会社 | 複素環化合物 |
| JP6581320B2 (ja) | 2017-02-08 | 2019-09-25 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 腫瘍治療用医薬組成物 |
| EP3624800A4 (en) | 2017-05-16 | 2021-02-17 | Eisai R&D Management Co., Ltd. | TREATMENT OF HEPATOCELLULAR CARCINOMA |
| CN110028444B (zh) * | 2019-05-28 | 2022-02-11 | 沈阳药科大学 | 1-芳基-3-[4-(吡啶-2-基甲氧基)苯基]脲类化合物及应用 |
| JP2022151436A (ja) * | 2021-03-26 | 2022-10-07 | 均 石井 | 髄膜炎と脳炎の治療薬。 |
| CN116354891B (zh) * | 2022-11-07 | 2025-01-07 | 河南省锐达医药科技有限公司 | 一种萘基苯醚类化合物、其制备方法及应用 |
| PL248268B1 (pl) * | 2023-04-13 | 2025-11-17 | Univ Medyczny W Lublinie | 1-(1-fenyloimidazolin-2-ylo)-3-aryloalkilo pochodne mocznika oraz sposób ich wytwarzania i ich zastosowanie |
| CN116987041A (zh) * | 2023-08-02 | 2023-11-03 | 河北科技大学 | 一种转移氢化法制备5-(2-氨基-4-氯苯基)四氮唑的方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU185294B (en) | 1980-12-29 | 1984-12-28 | Chinoin Gyogyszer Es Vegyeszet | Process for producing substituted urea derivatives |
| US4423126A (en) * | 1982-05-27 | 1983-12-27 | Eastman Kodak Company | Color-forming carboxamidonaphthalene dye precursor and carboximide dye in photographic material and process |
| GB8524157D0 (en) * | 1984-10-19 | 1985-11-06 | Ici America Inc | Heterocyclic amides |
| GB8908869D0 (en) | 1989-04-19 | 1989-06-07 | Shell Int Research | A process for the preparation of aromatic ureas |
| WO1991004027A1 (en) | 1989-09-15 | 1991-04-04 | Pfizer Inc. | New n-aryl and n-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme a: cholesterol acyl transferase (acat) |
| US5162360A (en) * | 1991-06-24 | 1992-11-10 | Warner-Lambert Company | 2-heteroatom containing urea and thiourea ACAT inhibitors |
| WO1993024458A1 (en) | 1992-05-28 | 1993-12-09 | Pfizer Inc. | New n-aryl and n-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (acat) |
| GB9302275D0 (en) | 1993-02-05 | 1993-03-24 | Smithkline Beecham Plc | Novel compounds |
| US5596001A (en) * | 1993-10-25 | 1997-01-21 | Pfizer Inc. | 4-aryl-3-(heteroarylureido)quinoline derivatves |
| EP0809492A4 (en) * | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| GB9511355D0 (en) * | 1995-06-06 | 1995-08-02 | Fujisawa Pharmaceutical Co | Urea derivatives |
| EP0859771A4 (en) | 1995-10-31 | 2000-03-15 | Merck & Co Inc | SUBSTITUTED PYRIDYLPYRROLE, PREPARATIONS CONTAINING SUCH COMPOUNDS AND METHOD FOR THE USE THEREOF |
| US6262113B1 (en) * | 1996-03-20 | 2001-07-17 | Smithkline Beecham Corporation | IL-8 receptor antagonists |
| DE19631303C2 (de) | 1996-08-02 | 1998-07-02 | Kettner Karl Ulrich Prof Dr | Vorrichtung zum Schutz von Gefäßen bei chirurgischen Eingriffen |
| AU7526798A (en) * | 1997-04-18 | 1998-11-27 | Smithkline Beecham Plc | Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders |
| WO1998052558A1 (en) * | 1997-05-23 | 1998-11-26 | Bayer Corporation | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS |
| WO1999007700A1 (en) * | 1997-08-09 | 1999-02-18 | Smithkline Beecham Plc | Bicyclic compounds as ligands for 5-ht1 receptors |
| AUPP003197A0 (en) * | 1997-09-03 | 1997-11-20 | Fujisawa Pharmaceutical Co., Ltd. | New heterocyclic compounds |
| WO1999023091A1 (en) * | 1997-11-03 | 1999-05-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
| AU2160899A (en) * | 1997-12-11 | 1999-06-28 | Janssen Pharmaceutica N.V. | Retinoic acid mimetic anilides |
| SK286213B6 (sk) * | 1997-12-22 | 2008-05-06 | Bayer Corporation | Substituované heterocyklické močoviny, farmaceutický prípravok ich obsahujúci a ich použitie |
| MXPA00006233A (es) * | 1997-12-22 | 2002-09-18 | Bayer Ag | Inhibicion de la actividad de la cinasa p38 utilizando ureas heterociclicas sustituidas. |
| DE69836563T2 (de) | 1997-12-22 | 2007-05-16 | Bayer Pharmaceuticals Corp., West Haven | INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYL-SUBSTITUIERTEN HARNSTOFFEN |
| JP3887769B2 (ja) * | 1997-12-22 | 2007-02-28 | バイエル コーポレイション | 対称および非対称ジフェニル尿素を用いるｐ３８キナーゼの阻害 |
| KR100320102B1 (ko) | 1998-11-21 | 2002-04-22 | 김원대 | 수직배향된나선변형강유전성액정표시장치 |
| US6166028A (en) * | 1998-12-09 | 2000-12-26 | American Home Products Corporation | Diaminopuridine-containing thiourea inhibitors of herpes viruses |
| NZ528846A (en) | 1999-03-12 | 2005-05-27 | Boehringer Ingelheim Pharma | Compounds useful as anti-inflammatory agents |
| WO2000055152A1 (en) * | 1999-03-12 | 2000-09-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as anti-inflammatory agents |
| ATE312823T1 (de) * | 1999-07-09 | 2005-12-15 | Boehringer Ingelheim Pharma | Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen |
| DE19934321A1 (de) * | 1999-07-21 | 2001-01-25 | Bayer Ag | Naphthyl-substituierte Sulfonamide |
-
2000
- 2000-11-16 WO PCT/US2000/031582 patent/WO2001036403A1/en not_active Ceased
- 2000-11-16 EP EP00978751A patent/EP1232150B1/en not_active Expired - Lifetime
- 2000-11-16 ES ES00978751T patent/ES2292488T3/es not_active Expired - Lifetime
- 2000-11-16 JP JP2001538892A patent/JP4955171B2/ja not_active Expired - Lifetime
- 2000-11-16 AT AT00978751T patent/ATE375334T1/de active
- 2000-11-16 US US09/714,539 patent/US6492393B1/en not_active Expired - Lifetime
- 2000-11-16 MX MXPA02004594A patent/MXPA02004594A/es active IP Right Grant
- 2000-11-16 AU AU16179/01A patent/AU1617901A/en not_active Abandoned
- 2000-11-16 CA CA002389360A patent/CA2389360C/en not_active Expired - Lifetime
- 2000-11-16 MX MXPA02004879A patent/MXPA02004879A/es unknown
- 2000-11-16 DE DE60036726T patent/DE60036726T2/de not_active Expired - Lifetime
-
2002
- 2002-10-15 US US10/271,301 patent/US7241758B2/en not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003514808A5 (https=) | ||
| JP2004531571A5 (https=) | ||
| JP2002539198A5 (https=) | ||
| JP4955171B2 (ja) | 抗炎症剤としての尿素誘導体 | |
| JP2005503400A5 (https=) | ||
| JP2002539206A5 (https=) | ||
| RU2004133034A (ru) | Новые фармацевтические композиции на основе антихолинергических средств и ингибиторов киназы р38 | |
| US7211575B2 (en) | Methods of treating cytokine mediated diseases | |
| RU2475487C2 (ru) | Имидазохинолины с иммуномодулирующими свойствами | |
| ES2225095T3 (es) | Urea herociclica y compuestos relacionados, utiles como agentes antiinflamatorios. | |
| JP2005518447A5 (https=) | ||
| CA2446193A1 (en) | 1,4-disubstituted benzo-fused cycloalkyl urea compounds | |
| JP2004536845A5 (https=) | ||
| RU2001126337A (ru) | Соединения, пригодные в качестве противовоспалительных агентов | |
| CA2352524A1 (en) | Aromatic heterocyclic compounds as antiinflammatory agents | |
| JP2004534787A5 (https=) | ||
| US20040110755A1 (en) | Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions | |
| FR2677019B1 (fr) | Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique. | |
| US20040033222A1 (en) | Anticoagulant and fibrinolytic therapy uning p38 MAP kinase inhibitors | |
| Way et al. | The toxicity and analgetic activity of some congeners of salicylamide | |
| JP2005538066A5 (https=) | ||
| JP3670292B2 (ja) | ケトニトリル誘導体及びこれを含有する抗菌剤及び医薬 | |
| AU2004200240B2 (en) | Compounds useful as anti-inflammatory agents | |
| RU2004121842A (ru) | Соединения, пригодные в качестве противовоспалительных агентов | |
| ZA200107446B (en) | Compounds useful as anti-inflammatory agents. |